By Sukhi Basra, Prescribing Pharmacist, Obesity Specialist, Vice Chair NPA.
If you’re currently using Mounjaro (tirzepatide) or considering it as part of your weight management plan, you’ve likely come across headlines about a sharp price increase. As your prescriber and someone deeply committed to ethical, clinically-sound care, I want to provide you with accurate, evidence-based information to help you navigate this change without panic or confusion.
Whether you’re a current patient or simply doing your research, here’s what you need to know.
What’s Happening With Mounjaro Pricing in the UK?
As of 1st September 2025, the manufacturer of Mounjaro, Eli Lilly, will significantly increase the cost of the medication in the UK. This decision applies to all providers and pharmacies, and is not something individual clinics have control over.
Why is the price going up?
According to Eli Lilly, the UK launch price for Mounjaro was initially set much lower than in other developed nations to enable rapid NHS access during supply constraints. However, this created a situation where:
- Overseas buyers were bulk-purchasing from the UK
- Supply chains were being strained
- Inconsistent pricing led to unfair global access
The company has stated the price increase is intended to bring the UK in line with international pricing and prevent misuse of supply.
“We are aligning the UK price with other developed markets to ensure sustainability and patient safety.”
— Eli Lilly UK, 2025
Source: Eli Lilly Press Releases
What Does This Mean for You?
Don’t Panic Here’s What You Should Know:
- This is not the result of your clinic changing prices independently.
- We will maintain current pricing as long as possible, while reviewing all supplier updates and rebate structures.
- Stock will be limited. Advance or bulk orders are not permitted. A maximum of two months’ supply will be dispensed per patient at a time, in line with national guidance.
Safe Prescribing Matters More Than Ever
There has been a rise in concerning trends across the private sector:
- Patients being escalated to 15mg doses within 6 months
- Minimal clinical oversight (no face-to-face reviews, no history taking)
- Online-only & other providers issuing prescriptions via questionnaires alone
“Patients are being escalated to maximum dose rapidly without the appropriate oversight.”
— Eli Lilly Obesity Division, 2025
This is why choosing a qualified, responsible prescriber is essential.
In my clinic, I ensure:
- Full medical reviews and pathology screening where needed.
- Face-to-face consultations
- Direct communication with your NHS GP (if appropriate)
- Ongoing support, dose management, and accountability
How to Manage Progress Without Compromising Safety
If you’re concerned about affordability or future access, here are some safe, supported options:
- Staying on a lower dose, if clinically appropriate
- Exploring alternatives like Wegovy, which is currently unaffected by these price changes
- Reviewing your progress regularly to ensure you’re getting the right balance between cost and outcome
“NICE guidelines recommend continuous clinical oversight when using GLP-1 receptor agonists.”
Source: NICE, 2023
Remember: Sustainable weight management includes more than medication.
I always encourage patients to build in:
- A nutrient-rich, balanced diet
- Regular, enjoyable physical activity
- Sleep and stress management routines
- Long-term behavioural support
FAQs
Q: Will Mounjaro become unaffordable for me?
We’re working hard to limit the impact. There are ways to adapt your plan safely, and you will never be left without options.
Q: Should I try to stockpile my medication?
No, national regulations now limit dispensing to a maximum of two months. Stockpiling is discouraged and may put others at risk.
Q: Is it safe to start Mounjaro now?
Yes, when prescribed and monitored correctly. It’s a highly effective medication, but like all treatments, it must be used responsibly.
I’m Advocating For You at a National Level
As Vice Chair of the National Pharmacy Association, I am actively involved in policy-level conversations, including presenting evidence to the London Assembly Obesity Inquiry. My role is to ensure that the patient voice is heard, and that ethical prescribers like myself can continue to deliver responsible, personalised care.
Final Thoughts
I know this news may feel unsettling, but please remember:
- You are not alone
- You are not powerless
- You are not without options
As your prescriber, I will continue to do everything I can to support your health, your choices, and your journey.
If you have questions, don’t hesitate to reach out directly. I will always provide honest, compassionate guidance.
Warmly,
Sukhi Basra
IP Pharmacist, Obesity Specialist, Vice Chair of NPA.
